Ozempic Ingredient Shows Anti-Aging Effects in Mice

A recent study funded by the National Institutes of Health suggests that semaglutide, the active ingredient in popular medications like Ozempic and Wegovy, may do more than just manage blood sugar and appetite. Researchers found that the drug extended the lifespan of older, healthy mice and improved several key markers of aging, including memory and muscle function.

The findings are significant because they indicate that these GLP-1 drugs might influence the fundamental biological processes of aging itself. While earlier studies showed benefits for specific age-related diseases, this research points to a broader effect on the body's overall aging trajectory, offering a potential explanation for the wide range of health improvements observed in clinical settings.

Lifespan gains observed in late-life mice

To test the drug's impact when aging was already well underway, a team at the University of California, Berkeley, administered semaglutide to female mice that were 20 months old. Over a three-month period, the treated animals demonstrated better cognitive performance and muscle strength compared to untreated controls. Gene activity analysis also revealed reduced inflammation and improved tissue repair capabilities, suggesting a tangible slowing of biological decline.

The most striking result was the extension of life. In a separate group of mice treated until death, those receiving semaglutide lived nearly 100 days longer on average than their untreated counterparts. This substantial increase in median lifespan provides strong preliminary evidence that the drug can alter the aging process even when started in later life stages.

Beyond the effects of eating less

Because semaglutide suppresses appetite, scientists needed to determine if the health benefits were simply due to calorie reduction. They compared the drug to a 24% calorie-restricted diet, matching the food intake of the treated mice. While both approaches improved many physiological markers, semaglutide showed distinct advantages in spatial memory and exploratory behavior. Additionally, the metabolic rate of the drug-treated mice remained stable, whereas it slowed in the diet-restricted group.

Implications for future longevity research

These differences suggest that GLP-1 drugs may activate biological pathways independent of caloric intake. According to Rafael de Cabo, a senior investigator at the NIH's National Institute on Aging, if these drugs truly slow the aging process, the broad clinical benefits seen in humans are expected outcomes. The study, reported by ScienceDaily, highlights a new direction for research into longevity-enhancing interventions that target the root causes of age-related decline.